| Literature DB >> 31846618 |
Daan J A Crommelin1, Peter van Hoogevest2, Gert Storm3.
Abstract
The rapid rise in interest in 'nanomedicines' in the academic world over the last twenty years and the claims of success led to calls for reflection. The main body of text of this Commentary will be on answering the question: 'where to go with nanomedicines'? Research priorities for the future will be outlined based on experience with the most successful nanomedicines family within the broad field of nanomedicine so far: liposomes. An analysis of currently clinically tested, approved and marketed liposome-drug combinations provides these insights.Keywords: Clinical trials; Liposomes; Nanomedicines
Mesh:
Substances:
Year: 2019 PMID: 31846618 DOI: 10.1016/j.jconrel.2019.12.023
Source DB: PubMed Journal: J Control Release ISSN: 0168-3659 Impact factor: 9.776